Thu, Oct 23, 2014, 2:43 AM EDT - U.S. Markets open in 6 hrs 47 mins

Recent

% | $
Quotes you view appear here for quick access.

Tengion, Inc. (TNGN) Message Board

drwestclone 27 posts  |  Last Activity: Oct 15, 2014 7:16 PM Member since: May 19, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • drwestclone drwestclone Oct 15, 2014 7:16 PM Flag

    Looks like the case....Here's today's news concerning ACTC's use of hESC's:

    TUESDAY, Oct. 14, 2014 (HealthDay News) -- A new study is the first to show the long-term safety of embryonic stem cell transplants to treat human disease.

    The research involved 18 people who received the transplants to treat forms of macular degeneration, a leading cause of vision loss.

    The transplants, which restored some sight in more than half of the patients, appeared safe up to three years after the procedure.

    The study, funded by a U.S.-based company called Advanced Cell Technology, was published Oct. 14 in The Lancet.

    "Embryonic stem cells have the potential to become any cell type in the body, but transplantation has been complicated by problems," lead author Dr. Robert Lanza, chief scientific officer at Advanced Cell Technology, said in a journal news release. Those problems include the rejection of the transplanted cells by the patient's immune system, as well as the danger that the cells might spur certain types of cancers called teratomas.

    A teratoma is a type of cancer that occurs when stem cells develop into multiple types of cells and form incompatible tissues that can include teeth and hair.

    As Lanza explained, because of these issues, scientists interested in embryonic stem cell therapy have tended to focused on sites in the body that typically do not produce a strong immune response. The eye is one such spot.

    In the new study, human embryonic stem cells were first prompted to develop into eye cells called retinal pigment epithelial cells. They were then transplanted into nine people with Stargardt's macular dystrophy, and another nine with dry atrophic age-related macular degeneration.

  • drwestclone drwestclone Oct 9, 2014 12:05 AM Flag

    These shares were sold over to institutions. Stop trying to scare people so YOU can buy more shares.

  • Reply to

    Bottoms in, PanC-DX to be announced

    by ipstissueface Oct 1, 2014 3:50 PM
    drwestclone drwestclone Oct 1, 2014 9:52 PM Flag

    Cedar Sinai, Weill Cornell on board, more major hospitals to jump on board soon!

  • OncoCyte to announce CE Mark in the EU for acceptance of PanC-DX cancer diagnostic products.
    Time to buy.

  • Reply to

    One more day to buy in

    by headsupeyesclosed Sep 25, 2014 11:15 AM
    drwestclone drwestclone Sep 25, 2014 2:42 PM Flag

    Will hit the market in EU first, and soon after get approval in US. Our partner Weil Cornell will be the first medical institution in US to actually use PanC-DX.

  • 1-Next week marks the beginning of numerous milestone announcements including restart of spine trials.
    
2-BTX in R&D/building phase for last seven years and finally about to announce multiple clinical trials

    3-Two 'low hanging fruit' products: lung cancer diagnostic product PanC-DX, LifeMap medical App.
    
4-BTX currently pulling out of a 5 yr low
    5-Currenly holds most stem cell patents for one single company worldwide

    6-Balanced approach, with growing research products and many regen therapeutics on the way

    7-A+ biz plan with seven subsidiaries, no debt, world renowned CEO's & scientific leaders

    8-Building best in class corporate/institutional partners including, CIRM, TEVA, Weill Cornell, Wistar Institute, Mt Sini, Spain Stem Cell Center, USC, Millipore and more to be announced in coming weeks.
    
9-Owns worlds most popular online genetic database company LifeMaps which is currently developing next-gen personalized medicine app(partner: with Mt Sini Memorial genetic dept.).
    10-Recently IPO'ed first subsidiary Astrias, next year likely to have more IPO's
    Hope some have found this info useful !

  • “We are very pleased with the progress that Cell Cure’s team has made in preparing for the company’s FDA submission,” said Charles S. Irving PhD, Cell Cure’s CEO. “We look forward to initiating the clinical trial that will utilize for the first time high quality, xeno-free grade RPE cells for the treatment of geographic atrophy, the severe stage of dry-AMD.”

  • Reply to

    All you need to know

    by drwestclone Jul 10, 2014 4:13 PM
    drwestclone drwestclone Sep 18, 2014 12:10 AM Flag

    Yes you are a clown.... Counsyl, Inc v. Myriad Genetics, Inc patent lawsuit ...Do your D&D:

  • Some misinformation posted on this board by stock shorters.....let me post some facts here:

    
In 2010 BTX announced the start of their cancer diagnostics program...they INSTANTLY shot to an intra-day high of $10. Fast forward four yeas....BTX partners are growing, UCLA, Wistar Institute, Weill Cornell and now Abcodia Ltd. 

    Our first product to be released will most likely be PanC-DX for lung cancer, currently finishing up blood sample data with Weill Cornell and will be released in late 2014 in the EU.

  • drwestclone by drwestclone Sep 17, 2014 11:54 PM Flag

    Biotime is totally under the radar like most stem cell stocks. Later this year our cancer diagnostic products will start finishing trials, partner and prepare to hit the market. By early next year your average investor will take notice and talking heads like MadMoneys Cramer will start taking Lightning Round calls about us.

  • drwestclone by drwestclone Sep 10, 2014 2:38 PM Flag

    Just listened to today's presentation by Dr. west and here are a few quotes and tidbits I came away with:

    "Several milestones kicking in durning second half of this year as well as early next year."

    -Pre-clinical programs to start for MS and stroke
    -AMD (animal free) trials-TEVA partnership-start this year
    -Renevia, entering pivotal trial, 15 year patent life,cosmetic/HIV
    -Premivia FDA excepted, start tendon repair program
    -Oncocyte: late this year reporting on clinical trials for lung bladder and breast cancer diagnostics. "Breast cancer alone a 2 BIL market and replacement for mammography modality." "Bladder PanC-DX tests patients urine replacing biopsy, and lung PanC replacing low dose catscan for high risk patients."

  • Reply to

    AST is just one of Biotimes subsidiaries

    by btimnextmicrosoft Sep 8, 2014 6:25 PM
    drwestclone drwestclone Sep 9, 2014 11:39 AM Flag

    At this point BTX. World first cancer diagnostic product to be released in EU market by years end. Our nano breast cancer blood test is so sensitive it will replace the need for mammograms, and our bladder cancer PanC-DX is a urine test. Lung cancer being developed along with NYC Weil Cornell.
    And if that's not enough for you we also have LifeMap Medical research app 1.0 also out by years end.

  • Reply to

    Question about ASTY spinoff.

    by iconoclasticist Sep 4, 2014 3:21 PM
    drwestclone drwestclone Sep 5, 2014 5:07 PM Flag

    Icon, a few years ago hit an intra-day high of $10 when they announced the start of their cancer diagnostics program. It's been three years and our partners Wistar Institute and Weill Cornell are prepping release. First release to market will be in the EU before years end. I would expect BTX to have a major pop at that time.
    Best of luck!

  • Reply to

    BTX value

    by twicesilent23 Sep 5, 2014 10:44 AM
    drwestclone drwestclone Sep 5, 2014 4:03 PM Flag

    Thx for the explanation icon, good to have you aboard.

  • Reply to

    Question about ASTY spinoff.

    by iconoclasticist Sep 4, 2014 3:21 PM
    drwestclone drwestclone Sep 5, 2014 1:32 AM Flag

    icon, do you own BTX and AST? Always curious about newbies.
    Thx!

  • Reply to

    Dr. West's IPO treasure chest

    by ipstissueface Aug 21, 2014 8:44 PM
    drwestclone drwestclone Aug 22, 2014 1:25 PM Flag

    Thats the idea !

  • Reply to

    Btx steals exec from Pfizer

    by btimnextmicrosoft Aug 21, 2014 4:35 PM
    drwestclone drwestclone Aug 21, 2014 5:00 PM Flag

    Correction: BTX didn't 'steal' Nat Ricciardi, he spent nearly 40 years with Pfizer before retiring. Great pick up for AST's board no doubt.

  • Reply to

    BTX LifeMaps competition

    by drwestclone Aug 15, 2014 2:20 PM
    drwestclone drwestclone Aug 15, 2014 2:27 PM Flag

    LifeMap already has the largest researcher based genetic/stemcell database, an upgrade early next year should keep them at the forefront.

  • drwestclone by drwestclone Aug 15, 2014 2:20 PM Flag

    Stem Cell News today:
    In a boon to stem cell research and regenerative medicine, scientists at Boston Children's Hospital, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Boston University have created a computer algorithm called CellNet as a "roadmap" for cell and tissue engineering, to ensure that cells engineered in the lab have the same favorable properties as cells in our own bodies. CellNet and its application to stem cell engineering are described in two back-to-back papers in the August 14 issue of the journal Cell.

    Scientists around the world are engaged in culturing pluripotent stem cells (capable of forming all the body's tissues) and transforming them into specialized cell types for use in research and regenerative medicine. Available as an Internet resource for any scientist to use, CellNet provides a much needed "quality assurance" measure for this work.

  • Reply to

    This weeks news....so far

    by btimnextmicrosoft Aug 12, 2014 8:31 PM
    drwestclone drwestclone Aug 12, 2014 11:24 PM Flag

    Little by little coming out from under the radar. Cancer diagnostic products out early next year! Buy now before Wall St and Cramer start!

TNGN
0.020.00(0.00%)Oct 21 3:17 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.